CellSearchTM, the only FDA-cleared platform for clinical CTC testing, captures breast cancer CTCs based on the combination of EpCAM+ and cytokeratin+ (epithelial origin), and CD45− (for leukocyte depletion) biomarkers, leading to exclusion of non-epithelial or stem-like CTCs [17]. Here, PTPRC is linked to breast carcinoma.